[A18-38] Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06

Last updated 02.08.2018

Project no.:

Commission awarded on 12.06.2018 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:
Head and nerves


Adults with active relapsing multiple sclerosis (RMS) or with early primary progressive multiple sclerosis (PPMS)

Result of dossier assessment:

Active RMS: proof of considerable (< 40 years) or minor (≥ 40 years) added benefit; highly active RMS: added benefit not proven. PPMS: indication of lesser benefit than appropriate comparator therapy


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2018-08-02 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form